Zantac litigation

28 June 2024 -​Statement: Zantac (ranitidine) litigation – Gross case

GSK has reached a confidential settlement with Martin Gross resolving the case he filed.

10 June 2024 - Statement: Zantac (ranitidine) litigation - GSK starts process for appeal of recent Delaware Daubert decision

GSK confirms that the company has taken the first step to seek appeal of the recent Daubert ruling by the Delaware Superior Court.

10 June 2024 - Statement: Zantac (ranitidine) litigation - Kasza case

GSK welcomes the plaintiff's voluntary dismissal of the Kasza case previously pending in Illinois state court.

1 June 2024 - Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling

GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.

23 May 2024 - Statement: Zantac (ranitidine) litigation - Valadez and Williams cases

Jury in Valadez case in Illinois state court finds GSK and Boehringer Ingelheim not liable for plaintiff's colorectal cancer. Separately, the company welcomed the court ruling dismissing the Williams case that was due to start on 23 May 2024.

29 February 2024 - Statement: Zantac (ranitidine) litigation

GSK confirmed it has reached a confidential settlement with Boyd/Steenvoord.

1 February 2024 - Statement: Zantac (ranitidine) litigation

GSK today confirmed it has reached a confidential settlement with David Browne, resolving the case filed by Mr. Browne in California state court.

11 October 2023 - Statement: Zantac (ranitidine) litigation

GSK today confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court.

23 June 2023 - Statement: Zantac (ranitidine) litigation

GSK confirmed it had reached a confidential settlement with James Goetz, dismissing the case in California state court.

12 May 2023 - Statement: Zantac (ranitidine) litigation

GSK welcomes the decision of the British Columbia Supreme Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795 dismissing a proposed class action on behalf of a class of ranitidine users in Canada.

24 March 2023 - Statement: Zantac (ranitidine) litigation

GSK issued a statement in response to the Sargon ruling by the California state court in the Goetz case.

7 December 2022 - Statement: Zantac (ranitidine) litigation

The MDL Court dismissed all cases alleging the five remaining cancers in the MDL.

16 August 2022 - Statement: Zantac (ranitidine) litigation

Notice of plaintiff's voluntary dismissal in the Bayer case in Madison county, Illinois.

11 August 2022 - Statement Zantac (ranitidine) litigation

Response to speculative commentary regarding U.S. Zantac litigation.

Court decisions and filings:

• December 2022 - United States District Court Southern District of Florida Daubert order (Federal MDL - Judge Rosenberg)
• May 2024 - Superior Court of The State of Delaware Daubert Order (Delaware State Litigation - Judge Medinilla)
• June 2024 – GSK, Pfizer, Sanofi, and Boehringer Ingelheim’s Application for Interlocutory Review of The Court’s Denial of Defendants’ Motion to Exclude Plaintiffs’ General-Causation Experts (Delaware State Litigation)